Author: Alebund

March 29, 2024, Shanghai, China – Alebund Pharmaceuticals (“Alebund” or the “Company”), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to AP303 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

December 13, 2023, Shanghai, China—Alebund Pharmaceuticals (“Alebund” or the “Company”), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced phase II proof-of-concept study results for the investigational drug, AP306, a first-in-class, pan-inhibitor of sodium-dependent phosphate transporters, which was discovered by Chugai Pharmaceutical Co., Ltd., and previously referred by EOS789.

July 17 2023, Shanghai, China — Alebund Pharmaceuticals (“Alebund” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced that the first patient was enrolled and dosed on June 30 in its phase 3 trial “a randomized, open-label, multicenter phase 3 study to evaluate the efficacy and safety of AP301 on serum phosphorus control in dialysis patients with hyperphosphatemia ”(AP301-HP-02 Phase 3 Clinical Trial). Clinical trial information is available at www.chinadrugtrials.org.cn with identifier CTR20231624. Professor Li ZUO, Director of Department of Nephrology at Peking University People’s Hospital, acts as the leading investigator of the AP301 pivotal phase 3 clinical trial. The trial will be conducted in 50 sites and plan to enroll 472 hyperphosphatemia patients, among which 90% on hemodialysis and 10% on peritoneal dialysis.

Shanghai, China, April 12th, 2023—Alebund Pharmaceuticals (“Alebund” or the “Company”) announced that it has closed its Pre-C round financing, with close to RMB 200 million. Participants in this round include Yangzhou Guojin Investment, Jiangsu Dingxin Capital, Yangzhou Longchuan Holdings a leading international sovereign fund, Lilly Asia Venture, Quan Capital, 3H Health, Octagon Capital, and Verition Fund.

March 17, 2023, Shanghai, China—Alebund Pharmaceuticals (“Alebund” or the “Company”) announced that China’s National Medical Products Administration (NMPA) has granted approval for the company’s IND application for a phase 3 study of AP301 to treat hyperphosphatemia in dialysis patients.

Yangzhou, China, Dec. 7, 2021 – Alebund Pharmaceuticals (“Alebund” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, held today a groundbreaking ceremony for its research and production plant in Jiangsu province’s Yangzhou city.

Shanghai, China, Sep. 14, 2021 – Alebund Pharmaceuticals (“Alebund” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced that it has secured $54.5 million in its Series B+ financing round. This round was led by 3H Health Investment, Loyal Valley Capital and Morningside Ventures, followed by YuanBio Venture Capital, Octagon Capital, Verition Fund Management and HT Capital. Existing Shareholders including Lilly Asia Ventures, Quan Capital, a prominent sovereign wealth fund, 3E Bioventures Capital and Sherpa Healthcare Partners also took part in the financing. Proceeds raised in this round will help accelerate the development of Alebund’s clinical programs, the construction of the manufacturing site, the research of pre-clinical assets, and the expansion of Company’s talent pool.